Intec 000 411 the main force to continue to Masukura clear afternoon will soon break up Money Tips

Category: Money tips Release Date: 2006-01-19

Source: Tianxin Investment Authors: Yong You-Jie

Re-created the company's main business will be big pharmaceutical chain business development opportunities. A country's largest medical logistics center is being turned out to! Large modern pharmaceutical logistics distribution center is the construction of Intel pharmaceutical industry base "key", according to company development planning, will be in the industrial base building 3 million square meters of pharmaceutical logistics distribution center. This large-scale modern pharmaceutical logistics distribution center will have the storage, custody and other functions based on an integrated set of transportation, conservation, collating, sorting, delivery , delivery and a series of value-added features to further improve the Intel Pharmaceutical Sales - Information - Distribution integrated service system for manufacturers, distributors, retailers and end users, and multi-functional, integrated comprehensive services .

In addition, the industrial base within the pharmaceutical trade center construction plan of 4,000 square meters, the administrative headquarters of the construction plan of 1,000 square meters. At Interlagos pharmaceutical industry base is completed, will be able to support Intel Pharmaceutical five billion yuan of sales logistics security, and ultimately provide 10 billion yuan sales logistics capabilities. industrial base to support sales of varieties will be able to reach a thousand, with support for downstream clients (pharmaceutical companies, hospitals and pharmacies) terminals up to 2 million. industrial base to support every Day order processing capacity of up to 8000 shipments per day, of which more than 2,000 pieces of demolition zero consolidation, processing orders for 1500, picking 15000 times, and eventually form a logistics network covering the whole country.

From the stock reform in the top ten outstanding shares, to compare the quarterly report of the top ten outstanding shares, we will find the largest shareholder of corporate stock in the secondary market, the recent large-scale buying in just 14 trading days has become the first large flow of shareholders, should focus on in-depth attention. Pre-10 to send the unit price of 2.80 on the stock, the main continue to Masukura clear afternoon will soon break up, it is recommended to focus on.

Historical Information: Intel Group (000,411): there is room for upward adjustment of the price level of July 5, 2006

Source: Huatai Securities

Intec (000,411) has announced the share reform program, the circulation of shareholders holding 10 shares to be paid for every 2.3 shares of stock, non-tradable shareholders, the implementation of the arrangements on the price of shares in the total number of 7,252,068 shares. To change the company's stock price and the major shareholders of the low proportion of the cost of ownership and restructuring, said the relative, but lower than the market average, there are some upside. In recent years, China's pharmaceutical distribution area through the market-oriented reforms, the introduction of a collective, private and other pharmaceutical commercial enterprises, accelerated competition in the field of medicine circulation, which Intel Group, in the long run be beneficial, but its profitability Circulation is also subject to China's medical status and its own scale.
The current domestic medicine circulation tend to have 6-7 links, medicine, after most of the factory and subject to the wholesale business, retail chain) business or hospital pharmacy and many other links to reach consumers, many times the transfer of ownership of the goods is bound to affect the drug velocity, but also increased the cost of medicines in circulation. As the majority of pharmaceutical logistics distribution companies are not high, the cost high, leading to the root causes of the high cost of distribution. Industry net profit margin has been below 1%.
After years of pharmaceutical business integration, and nearly three years, industry-wide losses, experiencing growing pains, industry consolidation speed has been greatly improved. Although there is a further decline in gross profit margin of space, but the net profit margin has entered a stable phase. Under the guidance of state policies, pharmaceutical distribution business operating environment is changing for the better. Instance, circulation continued to decline in the level of direct concept of logistics in the industry has been generally recognized.
Brief: Zhejiang Pharmaceutical company as a regional leader in circulation, in the province has strong competitiveness; but the future is to develop as a regional leader, East China, the current sales, or slightly too small. The company occupied more cash in the cash flow might be affected. To the company at around 2.5 billion sales revenue would be used as a competitive regional leaders also need to grow.